Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Cell"
DOI: 10.1016/j.ccell.2020.04.013
Abstract: Summary Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising therapeutic activities in cancer and autoimmunity, respectively. We previously showed that epitope and isotype interact to deliver optimal agonistic anti-CD40 mAbs. The impact… read more here.
Keywords: antitumor activity; isotype; isotype switching; anti cd40 ... See more keywords
Polymer Micropatches as B-Cell Engagers.
Sign Up to like & getrecommendations! Published in 2024 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.4c04385
Abstract: B cells, despite their several unique functionalities, remain largely untapped for use as an adoptive cell therapy and are limited to in vitro use for antibody production. B cells can be easily sourced, they possess… read more here.
Keywords: cell engagers; micropatches cell; mace; polymer micropatches ... See more keywords
Tumor localized agonistic anti-CD40 therapy and beyond
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1713084
Abstract: The field of anti-CD40 agonistic antibody therapies is still awaiting the breakthrough in the clinic. Anti-CD40 agonistic antibodies should in theory complement anti-PD1/PDL1 therapy as they provide the necessary CD40 stimulation to antigen-presenting cells, thereby… read more here.
Keywords: therapy; anti tumor; anti cd40; tumor ... See more keywords
Ion Transport Basis of Diarrhea, Paneth Cell Metaplasia, and Upregulation of Mechanosensory Pathway in Anti-CD40 Colitis Mice.
Sign Up to like & getrecommendations! Published in 2024 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izae002
Abstract: BACKGROUND Anti-Cluster of differentiation (CD)-40-induced colitis, driven by innate inflammatory responses in the intestine, is a potent animal model exhibiting IBD pathophysiology including diarrhea. However, the ion transport basis of diarrhea and some key mucosal… read more here.
Keywords: mechanosensory; cell; paneth cell; anti cd40 ... See more keywords
Addition of Anti-CD40 Monoclonal Antibody to Nonmyeloablative Conditioning With Belatacept Abrogated Allograft Tolerance Despite Induction of Mixed Chimerism
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation"
DOI: 10.1097/tp.0000000000002417
Abstract: Background We recently reported anti-CD40 monoclonal antibody and rapamycin (aCD40/rapa) to be a reliable, nontoxic, immunosuppressive regimen for combined islet and kidney transplantation (CIKTx) in nonhuman primates. In the current study, we attempted to induce… read more here.
Keywords: allograft tolerance; monoclonal antibody; chimerism; mixed chimerism ... See more keywords
Anti‐CD40 antibody 2C10 binds to a conformational epitope at the CD40‐CD154 interface that is conserved among primate species
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Transplantation"
DOI: 10.1111/ajt.15574
Abstract: The antagonistic anti‐CD40 antibody, 2C10, and its recombinant primate derivative, 2C10R4, are potent immunosuppressive antibodies whose utility in allo‐ and xenotransplantation have been demonstrated in nonhuman primate studies. In this study, we defined the 2C10… read more here.
Keywords: cd40 antibody; anti cd40; cd40; 2c10 binding ... See more keywords
Developing a translational murine‐to‐canine pathway for an IL‐2/agonist anti‐CD40 antibody cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Veterinary and Comparative Oncology"
DOI: 10.1111/vco.12813
Abstract: Abstract Human and canine sarcomas are difficult to treat soft tissue malignancies with an urgent need for new improved therapeutic options. Local recurrence rates for humans are between 10%–30%, and 30%–40% develop metastases. Outcomes for… read more here.
Keywords: cd40 antibody; cancer; canine; cd40 ... See more keywords
Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005718
Abstract: Background Agonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as promising immunotherapeutic compounds with impressive antitumor effects in mouse models. However, preclinical and clinical studies faced dose-limiting toxicities mediated by necroinflammatory liver disease. An effective prophylactic… read more here.
Keywords: liver toxicity; liver; anti cd40; antibody ... See more keywords
Abstract 1531: Human anti-CD40 agonistic antibodies with enhanced FcgR engagement activate immune cell and promote anti-tumor efficacy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1531
Abstract: Checkpoint inhibitors represent a major advance in cancer immunotherapy, and combinatorial immunotherapies with secondary drivers of anti-tumor immunity provide beneficial effects for patients that do not show a strong endogenous immune response. CD40 is a… read more here.
Keywords: cell; immune; anti cd40; anti tumor ... See more keywords
Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3287
Abstract: Stimulating innate immunity can potentially enable us to overcome resistance to PD-(L)1 blockade. We previously conducted a phase 1 trial of cabiralizumab (anti-CSF1R) with sotigalimab (CD40 agonistic antibody) and nivolumab. Our purpose was to determine… read more here.
Keywords: csf1r; anti cd40; anti csf1r; anti anti ... See more keywords
Abstract 6085: Engineered anti-CD40 agonist antibody as a novel cancer neoantigen vaccine carrier
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6085
Abstract: Somatic mutations in cancer cells lead to the expression of neoantigens that can be targeted by personalized vaccines utilizing patient’s own host immune system to fight against cancer. However, current personalized cancer vaccines have shown… read more here.
Keywords: cancer; antibody; cd40 msas; vaccine ... See more keywords